GALDERMA GROUP AG (NYSE:GALDY) — Market Cap & Net Worth
Market Cap & Net Worth: GALDERMA GROUP AG (GALDY)
GALDERMA GROUP AG (NYSE:GALDY) has a market capitalization of $45.88 Billion ($45.88 Billion) as of May 3, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #572 globally and #277 in its home market, demonstrating a 3.64% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GALDERMA GROUP AG's stock price $42.09 by its total outstanding shares 1172843625 (1.17 Billion). Analyse GALDERMA GROUP AG (GALDY) cash flow conversion to see how efficiently the company converts income to cash.
GALDERMA GROUP AG Market Cap History: 2025 to 2026
GALDERMA GROUP AG's market capitalization history from 2025 to 2026. Data shows growth from $48.61 Billion to $49.36 Billion (0.00% CAGR).
GALDERMA GROUP AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GALDERMA GROUP AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
9.28x
GALDERMA GROUP AG's market cap is 9.28 times its annual revenue
Latest Price to Earnings (P/E) Ratio
79.31x
GALDERMA GROUP AG's market cap is 79.31 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $48.61 Billion | $5.24 Billion | $613.00 Million | 9.28x | 79.31x |
Competitor Companies of GALDY by Market Capitalization
Companies near GALDERMA GROUP AG in the global market cap rankings as of May 3, 2026.
Key companies related to GALDERMA GROUP AG by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #636 globally with a market cap of $41.77 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #692 globally with a market cap of $38.58 Billion USD ( €33.00 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #636 | Haleon plc | NYSE:HLN | $41.77 Billion | $9.38 |
| #692 | Takeda Pharmaceutical Company Limited | F:TKDA | $38.58 Billion | €13.80 |
GALDERMA GROUP AG Historical Marketcap From 2025 to 2026
Between 2025 and today, GALDERMA GROUP AG's market cap moved from $48.61 Billion to $ 49.36 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $49.36 Billion | +1.54% |
| 2025 | $48.61 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of GALDERMA GROUP AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $45.88 Billion USD |
| MoneyControl | $45.88 Billion USD |
| MarketWatch | $45.88 Billion USD |
| marketcap.company | $45.88 Billion USD |
| Reuters | $45.88 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GALDERMA GROUP AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epi… Read more